Erythema gyratum repens: Difference between revisions

Jump to navigation Jump to search
Line 42: Line 42:


==Epidemiology and Demographics==
==Epidemiology and Demographics==
EGR commonly affects Caucasians, with an average age of onset in the seventh decade of life (an average age of 63 years), and the male to female ratio is 2:1. EGR is usually precedes the diagnosis of the associated cancer by several months. EGR is mainly seen in patients with paraneoplastic syndrome, it can rarely be seen in patients with nonneoplastic conditions such as tuberculosis, hypereosinophilic syndrome, bullous pemphigoid vulgaris, systemic lupus erythematosis, and ulcerative colitis. 
* EGR is a rare dermatologic disease
'''Age'''
* The average age of onset of EGR is in the seventh decade of life
'''Gender'''
* The male to female ratio is 2:1
'''Race'''
* EGR commonly affects Caucasians


==Risk Factors==
==Risk Factors==

Revision as of 12:24, 20 June 2019

WikiDoc Resources for Erythema gyratum repens

Articles

Most recent articles on Erythema gyratum repens

Most cited articles on Erythema gyratum repens

Review articles on Erythema gyratum repens

Articles on Erythema gyratum repens in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Erythema gyratum repens

Images of Erythema gyratum repens

Photos of Erythema gyratum repens

Podcasts & MP3s on Erythema gyratum repens

Videos on Erythema gyratum repens

Evidence Based Medicine

Cochrane Collaboration on Erythema gyratum repens

Bandolier on Erythema gyratum repens

TRIP on Erythema gyratum repens

Clinical Trials

Ongoing Trials on Erythema gyratum repens at Clinical Trials.gov

Trial results on Erythema gyratum repens

Clinical Trials on Erythema gyratum repens at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythema gyratum repens

NICE Guidance on Erythema gyratum repens

NHS PRODIGY Guidance

FDA on Erythema gyratum repens

CDC on Erythema gyratum repens

Books

Books on Erythema gyratum repens

News

Erythema gyratum repens in the news

Be alerted to news on Erythema gyratum repens

News trends on Erythema gyratum repens

Commentary

Blogs on Erythema gyratum repens

Definitions

Definitions of Erythema gyratum repens

Patient Resources / Community

Patient resources on Erythema gyratum repens

Discussion groups on Erythema gyratum repens

Patient Handouts on Erythema gyratum repens

Directions to Hospitals Treating Erythema gyratum repens

Risk calculators and risk factors for Erythema gyratum repens

Healthcare Provider Resources

Symptoms of Erythema gyratum repens

Causes & Risk Factors for Erythema gyratum repens

Diagnostic studies for Erythema gyratum repens

Treatment of Erythema gyratum repens

Continuing Medical Education (CME)

CME Programs on Erythema gyratum repens

International

Erythema gyratum repens en Espanol

Erythema gyratum repens en Francais

Business

Erythema gyratum repens in the Marketplace

Patents on Erythema gyratum repens

Experimental / Informatics

List of terms related to Erythema gyratum repens

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Synonyms and keywords: Gammel's disease.


Overview

Historical Perspective

  • In 1953, the dermatologist, Dr. John A Gammel who was trained to link skin lesions to internal malignancy was the first one who described and labeled Erythema Granulatum Repens in a 55-year-old patient with poorly differentiated breast adenocarcinoma
  • Up to 1992, there were only 49 cases in the literature, 41 of which (84%) were associated with a neoplasm
  • EGR is associated with internal malignancy in 82% of cases. However, between 1990 and 2010, data was collected from the medical records of patients form dermatology department in University of Genoa and from databases as pubmed and medline, the conclusion of this literature review was that EGR is no longer considered as an obligate paraneoplastic syndrome. More than expected cases of EGR were found with no neoplasm association. Non-paraneoplastic EGR could be:
    • Idiopathic EGR
    • EGR-like eruptions (different dermatologic lesions that mimic EGR)
    • Drug-induced EGR


Classification

  • There is no established system for the classification of EGR.

Pathophysiology

  • The cause of EGR has not been identified.
  • Many theories suggest that EGR is due to immunologic mechanisms
  • The immunologic mechanism theory is evidenced by the observed immunofluorescence patterns of IgG, C3, and C4 at the basement membrane
    • Theory 1 the tumor induces antibodies that cross-react with the basement membrane of skin
    • Theory 2 the tumor produces polypeptides that bind skin antigens and render them immunogenic 
    • Theory 3 deposition of tumor antigen-antibody complexes onto the basement membrane causes the reactive dermatitis seen in EGR


Causes

The cause of erythema gyratum repens has not been identified.

Differentiating ((Page name)) from Other Diseases

  • EGR has a narrow differential diagnosis and it has to be differentiated from skin lesions with gyrate erythematous eruptions, such as:
    • Necrolytic migratory erythema (NME)
    • Erythema annulare centrifugum (EAC)
    • Erythema migrans

Epidemiology and Demographics

  • EGR is a rare dermatologic disease

Age

  • The average age of onset of EGR is in the seventh decade of life

Gender

  • The male to female ratio is 2:1

Race

  • EGR commonly affects Caucasians

Risk Factors

There are no established risk factors for EGR.

Screening

There is no screening tests for EGR but the skin rash shouldn't be missed in the the ED and patients should be referred for urgent evaluation and screening for internal malignancies.

Natural History, Complications, and Prognosis

Patients with EGR usually presents with the severely pruritic rash few months prior to the diagnosis of the internal malignancy. The pruritus can be debilitating and it may persist to the time of death.

Diagnosis

Diagnostic Study of Choice

EGR is mainly diagnosed clinically. Eosinophilia is observed in 60% of cases and immunofluorescence shows patterns of IgG, C3, and C4 at the basement membrane.

History and Symptoms

The hallmark of EGR is skin rash and pruritus is almost a universal symptom that can be extreme and debilitating. Patient may also complain of weight loss, anorexia, fatigue, and fever.

Physical Examination

Patients with EGR presents with a rash consisting of wavy erythematous concentric bands that can be figurate, gyrate, or annular. The bands are arranged in parallel rings and lined by a fine trailing edge of scale, a pattern often described as “wood grained. The rash typically involves large areas of the body but tends to spare the face, hands, and feet and it can expands as fast as a cm a day. Bullae can also form from within the areas of erythema.

Laboratory Findings

There are no diagnostic laboratory findings associated with EGR.

Electrocardiogram

There are no ECG findings associated with EGR.

X-ray

There are no x-ray findings associated with EGR.

Echocardiography or Ultrasound

There are no echocardiography/ultrasound findings associated with EGR.

CT scan

CT findings could be seen in the associated visceral malignancy in EGR.

MRI

There are no MRI findings associated with EGR.

Other Imaging Findings

Other Diagnostic Studies

Although skin appearance is characteristic, EGR has nonspecific histopathologic features. Biopsy specimens display acanthosis, mild hyperkeratosis, focal parakeratosis, and spongiosis confined to the epidermis and superficial dermis. Mononuclear, lymphocytic, and histiocytic perivascular infiltrate in the superficial plexus can also be seen. Basement membrane deposits of IgG, C3, or C4 have been noted under direct immunofluorescence in some cases.

Treatment

Various dermatologic and immunosuppressive therapies have been used to treat EGR. Systemic steroids are frequently ineffective. Topical steroids, vitamin A, and azathioprine have also failed to relieve skin manifestations. Improvement or resolution of EGR, and its associated intense pruritus, depends on recognition and treatment of the underlying malignancy. In patients with widely metastatic disease, the response of EGR to chemotherapy is variable. In such cases, patients may not experience resolution of the rash until just before the time of death, a time of significant immunosuppression

Medical Therapy

There is no treatment for EGR]; the mainstay of therapy is underlying malignancy.

Surgery

Surgical intervention is not recommended for the management of EGR.

Primary Prevention

There are no established measures for the primary prevention of EGR.

Secondary Prevention

There are no established measures for the secondary prevention of EGR.

References

Template:WikiDoc Sources